Wall Street is positive on Constellation Pharmaceuticals Inc (CNST). On average, analysts give CNST a Strong Buy rating. The average price target is $44.7, which means analysts expect the stock to add by 40.17% over the next twelve months.
That average ranking earns CNST an Analyst Rating of 66, which is better than 66% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Constellation Pharmaceuticals Inc Stock Today?
Constellation Pharmaceuticals Inc (CNST) stock is up 7.48% while the S&P 500 has fallen -0.45% as of 3:01 PM on Friday, Jan 15. CNST is higher by $2.22 from the previous closing price of $29.67 on volume of 302,150 shares. Over the past year the S&P 500 is higher by 13.92% while CNST has fallen -15.30%. CNST lost -$2.29 per share the over the last 12 months.
Click Here to get the full report on Constellation Pharmaceuticals Inc (CNST) Stock.
